MAIA Biotechnology (MAIA) Common Equity (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Common Equity for 6 consecutive years, with $20.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 433.32% year-over-year to $20.7 million in Q2 2026; TTM through Jun 2026 was $20.7 million, a 433.32% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, down 34.63% from the prior year.
• Common Equity was $20.7 million for Q2 2026 at MAIA Biotechnology, down from $27.8 million in the prior quarter.
• Over five years, Common Equity peaked at $27.8 million in Q1 2026 and troughed at -$5.8 million in Q1 2024.
• A 5-year average of $6.3 million and a median of $4.4 million in 2025 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 661.16% in 2024, down 213.41% in 2024.
• Over 5 years, Common Equity stood at $8.5 million in 2022, then slumped by 94.39% to $477511.0 in 2023, then soared by 661.16% to $3.6 million in 2024, then plunged by 34.63% to $2.4 million in 2025, then surged by 770.21% to $20.7 million in 2026.
• The last three Common Equity figures came in at $20.7 million (Q2 2026), $27.8 million (Q1 2026), and $2.4 million (Q4 2025), per Business Quant data.